DCVax-L for treating glioblastoma [ID836]

  • In development
  • GID-TA10143
  • Expected publication date: TBC
NICE is continuing to liaise with Northwest Biotherapeutics. The company reports that it is still fully occupied and engaged in the Marketing Authorisation Application (MAA) process with the MHRA.